Professor David Kerr, CBE. is a Professor of Cancer Medicine at the University of Oxford, England. He focuses on innovative approaches to cancer treatment, including novel biomarkers and inhibitors of key chemical pathways, and his research has contributed to saving thousands of lives over the past 20 years.
He has made significant contributions to reforming the UK’s National Health Service as a Founding Commissioner for Health Improvement, and developed a 20-year plan for the future of the NHS in Scotland, known as the ‘Kerr Report’. He has also established INDOX and AfrOx to improve quality of cancer care in India and Sub Saharan Africa, and has served as Health Advisor to two British Prime Ministers.
Professor Kerr has been distinguished with the first Nye Bevan award for Innovation by the NHS (2000), elected Fellow of the Academy of Medical Sciences (2000), honorary Fellow of the Royal College of General Practitioners (2007), the ESMO award for distinguished contribution to cancer therapy and research (2006) and appointed a Commander of the Order of the British Empire by HM the Queen (2002).
Professor Kerr was the Chief Research Advisor and Member of the Supreme Council of Health in Qatar (2009-10), and the ESMO President (2010-12). His patents have launched biotech spinout companies such as Cobra Therapeutics, Celleron and Oxford Cancer Biomarkers.
To date, he has secured over £60 million worth of scientific funding and grants, and co-authored over 400 articles in peer-reviewed journals such as the New England Journal of Medicine, The Lancet and Nature Genetics. He was Editor-in-Chief for Annals of Oncology between 2001-08, and Founding Editor in Chief of the Journal of Global Oncology, 2015-17.